Skip to main content
. 2014 May 27;32(19):2010–2017. doi: 10.1200/JCO.2013.49.3676

Table 1.

Characteristics of Patients With Early-Stage Breast Cancer Younger Than Age 65 Years According to Chemotherapy Regimen

Variable Total (N = 9,327)
TC (n = 1,060)
AC (n = 2,889)
TAC (n = 1,516)
AC + T (n = 894)
ddAC + P (n = 2,657)
AC + wP (n = 311)
P
No. % No. % No. % No. % No. % No. % No. %
Age, years < .001
    Range 23-64 26-64 24-64 27-64 27-64 23-64 30-64
    Mean 51 ± 8 52 ± 7 52 ± 8 50 ± 8 51 ± 8 50 ± 8 51 ± 8
    Median 52 52 52 51 52 51 52
    < 35 271 2.9 18 1.7 65 2.2 57 3.8 18 2.0 102 3.8 11 3.5
    35-44 1,734 18.6 176 16.6 451 15.6 310 20.4 169 18.9 561 21.1 67 21.5
    45-54 3,929 42.1 436 41.1 1,240 42.9 673 44.4 360 40.3 1,111 41.8 109 35.0
    55-64 3,393 36.4 430 40.6 1,133 39.2 476 31.4 347 38.8 883 33.2 124 39.9
Region* < .001
    Northeast 694 7.4 84 7.9 200 6.9 89 5.9 32 3.6 275 10.4 14 4.5
    North Central 2,454 26.3 234 22.1 796 27.6 309 20.4 193 21.6 829 31.2 93 29.9
    South 4,689 50.3 578 54.5 1,412 48.9 884 58.3 516 57.7 1,130 42.5 169 54.3
    West 1,448 15.5 163 15.4 470 16.3 229 15.1 148 16.6 406 15.3 32 10.3
Surgery < .001
    Lumpectomy 4,701 50.4 579 54.6 1,754 60.7 631 41.6 369 41.3 1,234 46.4 134 43.1
    Mastectomy 4,529 48.6 470 44.3 1,099 38.0 871 57.5 515 57.6 1,397 52.6 177 56.9
    Axillary LND 97 1.0 11 1.0 36 1.2 14 0.9 ≤ 10 26 1.0 ≤ 10
Hormone therapy 5,018 53.8 607 57.3 1,592 55.1 815 53.8 432 48.3 1,431 53.9 141 45.3 < .001
G-CSF primary prophylaxis 4,701 50.4 518 48.9 597 20.7 1,204 79.4 220 24.6 ,2089 78.6 73 23.5 < .001
Hospitalization in previous 90 days 394 4.2 49 4.6 105 3.6 76 5.0 46 5.1 107 4.0 11 3.5 .172

Abbreviations: AC, doxorubicin and cyclophosphamide; AC + T, doxorubicin and cyclophosphamide followed or preceded by docetaxel; AC + wP, doxorubicin and cyclophosphamide followed or preceded by weekly paclitaxel; ddAC + P, dose-dense doxorubicin and cyclophosphamide followed or preceded by paclitaxel; G-CSF, granulocyte colony-stimulating factor; LND, lymph node dissection; TAC, docetaxel, doxorubicin, and cyclophosphamide; TC, docetaxel and cyclophosphamide.

*

Unknown in 42 patients.

Received tamoxifen or an aromatase inhibitor.

Occurring within 90 days before initiation of chemotherapy.